{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:09:08Z","timestamp":1792030148283,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacc.2017.11.014","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T14:05:17Z","timestamp":1515420317000},"page":"177-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":478,"title":["NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk\u00a0of\u00a0Cardiovascular Disease and Aortic\u00a0Stenosis"],"prefix":"10.1016","volume":"71","author":[{"given":"Sotirios","family":"Tsimikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gissette","family":"Reyes-Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simhan","family":"Danthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.11.014_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","article-title":"Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients","volume":"37","author":"Moriarty","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib3","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2017.11.014_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/ATVBAHA.116.307995","article-title":"Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy-brief report","volume":"37","author":"Verbeek","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.11.014_bib6","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.11.014_bib7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib8","doi-asserted-by":"crossref","first-page":"e003012","DOI":"10.1161\/JAHA.115.003012","article-title":"Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS)","volume":"5","author":"Afshar","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2017.11.014_bib9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.11.014_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib15","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","article-title":"Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists","volume":"5","author":"Davidson","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.11.014_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"'LDL-C'\u00a0=\u00a0LDL-C\u00a0+ Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2017.11.014_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 Inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib20","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib21","first-page":"419","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex\u00a0vivo","volume":"1","author":"Villard","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jacc.2017.11.014_bib22","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2017.11.014_bib23","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.M038877","article-title":"Scavenger receptor-BI is a receptor for lipoprotein(a)","volume":"54","author":"Yang","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCGENETICS.116.001402","article-title":"SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a)","volume":"9","author":"Yang","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2017.11.014_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.117.310700","article-title":"Novel lipoprotein(a) catabolism pathway via apolipoprotein(a) recycling: adding the plasminogen receptor PlgRKT to the list","volume":"120","author":"Yeang","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","article-title":"Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a)","volume":"120","author":"Sharma","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib27","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50 Suppl","author":"Berliner","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.15252\/emmm.201404170","article-title":"Targeting macrophage histone deacetylase 3 stabilizes atherosclerotic lesions","volume":"6","author":"Hoeksema","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jacc.2017.11.014_bib29","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib30","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.11.014_bib31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.11.014_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10557-015-6634-1","article-title":"Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis","volume":"30","author":"Yeang","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2017.11.014_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1194\/jlr.M400496-JLR200","article-title":"Phosphocholine as a pattern recognition ligand for CD36","volume":"46","author":"Boullier","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1194\/jlr.M400467-JLR200","article-title":"High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins","volume":"46","author":"Schneider","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2017.11.014_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1194\/jlr.P054569","article-title":"Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies","volume":"56","author":"Tsiantoulas","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib37","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.110.234138","article-title":"Calcific aortic valve stenosis: methods, models, and mechanisms","volume":"108","author":"Miller","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib38","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2017.11.014_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2017.11.014_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib41","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2017.11.014_bib42","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.11.014_bib43","first-page":"A18484","article-title":"Modest potential association between reductions in lipoprotein(a) and major adverse cardiovascular events in the phase 3 trials of alirocumab versus control (abstr)","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and White subjects: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"The LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib46","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.11.014_bib48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacl.2017.03.001","article-title":"Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin\/kexin type 9","volume":"11","author":"Edmiston","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.11.014_bib49","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2017.11.014_bib51","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/ncomms6068","article-title":"Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins","volume":"5","author":"Postmus","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2017.11.014_bib52","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2017.11.014_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2017.11.014_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.11.014_bib55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2017.11.014_bib56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib57","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.116.026103","article-title":"A\u00a0replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.11.014_bib59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/joim.12519","article-title":"Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic\u00a0valve stenosis in patients with coronary artery disease","volume":"280","author":"Nsaibia","year":"2016","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2017.11.014_bib60","first-page":"229","article-title":"Lipoprotein(a)-associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis","volume":"2","author":"Torzewski","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jacc.2017.11.014_bib61","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: The Copenhagen General Population Study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib62","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/ATVBAHA.116.308271","article-title":"Estimating the population impact of lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report","volume":"36","author":"Afshar","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib63","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2015.06.1325","article-title":"Valvular (18)F-Fluoride and (18)F-fluorodeoxyglucose uptake predict disease progression and clinical outcome in patients with aortic stenosis","volume":"66","author":"Jenkins","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib64","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC Study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2017.11.014_bib65","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib66","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2012.073833","article-title":"Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children","volume":"98","author":"Goldenberg","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2017.11.014_bib67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2015.09.003","article-title":"Lipoprotein apheresis","volume":"45","author":"Moriarty","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacc.2017.11.014_bib68","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.11.014_bib69","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/eurheartj\/ehx352","article-title":"Adenoviral intramyocardial VEGF-D\u0394N\u0394C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I\/IIa study with 1-year follow-up","volume":"38","author":"Hartikainen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.11.014_bib70","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jacl.2015.07.006","article-title":"Lipoprotein(a): its relevance to the pediatric population","volume":"9","author":"McNeal","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2017.11.014_bib71","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2017.11.014_bib73","doi-asserted-by":"crossref","first-page":"e114519","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2017.11.014_bib74","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial","author":"Schwartz","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2017.11.014_bib76","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2017.11.014_bib77","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717416032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717416032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:15:14Z","timestamp":1760015714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717416032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0735109717416032"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk\u00a0of\u00a0Cardiovascular Disease and Aortic\u00a0Stenosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}